Mehmet UZUN, Aysu USUBBAYLI, Eda ÇALIŞKAN YILDIRIM, Aziz KARAOĞLU
ABS TRACT Objective: The classification of endometrial cancer, based on histology, provides important prognostic information and is pivotal for assessing appropriate surgical and adjuvant therapy. However, molecular determinants could be incorporated to improve the current classification system. Materials and Methods: In our study,Seventy patients diagnosed with endometrial cancer between 2016 and 2021 were included. Pathological type, stage at diagnosis, the date of initiation of treatment, survival information, and molecular characteristics of the patients were recorded.The chi-square test was used to analyze categorical variables.Independent groups were compared using an independent sample t-test and Mann-Whitney-U test. Overall survival was estimated using the Kaplan-Meier method, and results were compared using the log-rank test. The independent prognostic risk factors were analyzed using the Cox regression model. Results: The primary findings obtained were as follows: (1) Median overall survival in de novo metastatic cases was significantly lower than that in patients with subsequent relapse; (2) The most common endometrioid type was observed based on the histopathological examination results. The undifferentiated endometrial cancer sub-type demonstrated a highly aggressive course; (3) In the present study, p16 was positive at a significantly higher rate over 60 years of age (p = 0.027). Conclu-sion: Various prognostic factors were examined in this study. Molecular markers may have an important role in determining the prognosis of endometrial cancer. The positivity of molecular markers such as p16 may contribute to mortality, especially in the geriatric age group.
{"title":"Examination of Factors Affecting Prognosis and Treatment Choice in Patients with Endometrial Cancer: A Retrospective Single-Center Experience","authors":"Mehmet UZUN, Aysu USUBBAYLI, Eda ÇALIŞKAN YILDIRIM, Aziz KARAOĞLU","doi":"10.37047/jos.2022-92811","DOIUrl":"https://doi.org/10.37047/jos.2022-92811","url":null,"abstract":"ABS TRACT Objective: The classification of endometrial cancer, based on histology, provides important prognostic information and is pivotal for assessing appropriate surgical and adjuvant therapy. However, molecular determinants could be incorporated to improve the current classification system. Materials and Methods: In our study,Seventy patients diagnosed with endometrial cancer between 2016 and 2021 were included. Pathological type, stage at diagnosis, the date of initiation of treatment, survival information, and molecular characteristics of the patients were recorded.The chi-square test was used to analyze categorical variables.Independent groups were compared using an independent sample t-test and Mann-Whitney-U test. Overall survival was estimated using the Kaplan-Meier method, and results were compared using the log-rank test. The independent prognostic risk factors were analyzed using the Cox regression model. Results: The primary findings obtained were as follows: (1) Median overall survival in de novo metastatic cases was significantly lower than that in patients with subsequent relapse; (2) The most common endometrioid type was observed based on the histopathological examination results. The undifferentiated endometrial cancer sub-type demonstrated a highly aggressive course; (3) In the present study, p16 was positive at a significantly higher rate over 60 years of age (p = 0.027). Conclu-sion: Various prognostic factors were examined in this study. Molecular markers may have an important role in determining the prognosis of endometrial cancer. The positivity of molecular markers such as p16 may contribute to mortality, especially in the geriatric age group.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134887736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ABS TRACT Afatinib is an irreversible second-generation tyrosine kinase inhibitor. It is used to treat epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma. The most well-known side effects associated with afatinib are diarrhea, rashes or acne and stomatitis. Herein, we present a case of skin toxicity that developed in the late phase of afatinib treatment. A 51-year-old, non-smoker woman diagnosed with EGFR deletion-19 mutant advanced lung adenocarcinoma. Afatinib was initiated as the first-line treatment. At the twelfth treatment month, Grade-2 acneiform dermatitis, paronychia, and hand-foot syndrome developed. Despite the interruption or discontinuation of afatinib treatment and local/systemic steroid treatments, the lesions did not regress. The patient was responsive to afatinib; however, the treatment was discontinued in the eighteenth month of treatment. The treatment response may be predicted by the severity of skin toxicities owing to afa-tinib. They occur in the early treatment phase and are commonly observed at the Grade 1-2 level.
{"title":"Lung Carcinoma Developing Afatinib-Associated Skin Reactions","authors":"E. Karaman, A. Ulaş, Ayça ADIACAR SEZER","doi":"10.37047/jos.2022-92025","DOIUrl":"https://doi.org/10.37047/jos.2022-92025","url":null,"abstract":"ABS TRACT Afatinib is an irreversible second-generation tyrosine kinase inhibitor. It is used to treat epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma. The most well-known side effects associated with afatinib are diarrhea, rashes or acne and stomatitis. Herein, we present a case of skin toxicity that developed in the late phase of afatinib treatment. A 51-year-old, non-smoker woman diagnosed with EGFR deletion-19 mutant advanced lung adenocarcinoma. Afatinib was initiated as the first-line treatment. At the twelfth treatment month, Grade-2 acneiform dermatitis, paronychia, and hand-foot syndrome developed. Despite the interruption or discontinuation of afatinib treatment and local/systemic steroid treatments, the lesions did not regress. The patient was responsive to afatinib; however, the treatment was discontinued in the eighteenth month of treatment. The treatment response may be predicted by the severity of skin toxicities owing to afa-tinib. They occur in the early treatment phase and are commonly observed at the Grade 1-2 level.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69823998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Erkan ÖZCAN, Ahmet KÜÇÜKARDA, Ali GÖKYER, Sezin SAYIN, İvo GÖKMEN, Muhammet Bekir HACIOĞLU, Bülent ERDOĞAN, Sernaz TOPALOĞLU, İrfan ÇİÇİN
: This study aimed to compare the clinical features, prognosis, and survival rates of patients with small cell carcinoma of the lung or extrapulmonary origin to get a new perspective for customized treatment strategies for both diseases. Material and Methods: We evaluated 254 patients with either small cell lung carcinoma (SCLC) or extrapulmonary small cell carcinoma (EPSCC) who were diagnosed and treated at Trakya University Hospital, Department of Medical Oncology from 2010 to 2020. We also compared these groups regarding their disease control rate, disease-free survival (DFS) in the limited disease (LD) stage, radiological progression-free survival (PFS), and overall survival (OS). Results: The SCLC group showed a male predominance, which was statistically significant. There was a statistically significant difference was observed concerning bone and brain metastases in the SCLC group. The median DFS was 16.7 and 9.4 months in the EPSCC and the SCLC groups with LD, respectively. Additionally, PFS and OS were similar between LD and extensive disease (ED) stage patients, respectively. Several factors like the presence of liver metastasis at the time of diagnosis, patients >60 years, poor performance status, and high lactate dehydrogenase (LDH) levels were associated with poor OS in ED patients. Conclusion: Although a significant difference was observed in DFS between both groups in LD patients, there was no significant difference between OS and PFS in LD and ED patients of SCLC and EPSCC groups, respectively. Moreover, the presence of liver metastasis and high LDH levels were a few factors that negatively affected the OS of patients.
{"title":"Comparison of Extrapulmonary Small Cell Carcinoma and Small Cell Lung Carcinoma: A Single-Center Study","authors":"Erkan ÖZCAN, Ahmet KÜÇÜKARDA, Ali GÖKYER, Sezin SAYIN, İvo GÖKMEN, Muhammet Bekir HACIOĞLU, Bülent ERDOĞAN, Sernaz TOPALOĞLU, İrfan ÇİÇİN","doi":"10.37047/jos.2023-97197","DOIUrl":"https://doi.org/10.37047/jos.2023-97197","url":null,"abstract":": This study aimed to compare the clinical features, prognosis, and survival rates of patients with small cell carcinoma of the lung or extrapulmonary origin to get a new perspective for customized treatment strategies for both diseases. Material and Methods: We evaluated 254 patients with either small cell lung carcinoma (SCLC) or extrapulmonary small cell carcinoma (EPSCC) who were diagnosed and treated at Trakya University Hospital, Department of Medical Oncology from 2010 to 2020. We also compared these groups regarding their disease control rate, disease-free survival (DFS) in the limited disease (LD) stage, radiological progression-free survival (PFS), and overall survival (OS). Results: The SCLC group showed a male predominance, which was statistically significant. There was a statistically significant difference was observed concerning bone and brain metastases in the SCLC group. The median DFS was 16.7 and 9.4 months in the EPSCC and the SCLC groups with LD, respectively. Additionally, PFS and OS were similar between LD and extensive disease (ED) stage patients, respectively. Several factors like the presence of liver metastasis at the time of diagnosis, patients >60 years, poor performance status, and high lactate dehydrogenase (LDH) levels were associated with poor OS in ED patients. Conclusion: Although a significant difference was observed in DFS between both groups in LD patients, there was no significant difference between OS and PFS in LD and ED patients of SCLC and EPSCC groups, respectively. Moreover, the presence of liver metastasis and high LDH levels were a few factors that negatively affected the OS of patients.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"265 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134889778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Karadurmuş, N. Akyürek, A. Aydıner, R. Savaş, Özlem Sönmez, M. Şendur, B. Oyan, D. Yalman, Mehmet Ufuk Yilmaz, Ülkü Yılmaz, P. Yumuk, E. Göker
ABS TRACT Lung cancer is one of the leading causes of cancer-related deaths in men and women. Similar to the approach with other cancer types, lung cancer staging is crucial in planning an effective treatment plan and predicting patient prognosis. Effective immunotherapies for patients with non-small cell lung cancer and non-genomic driver mutations are rapidly evolving. Moreover, anti-programmed death receptor-1 (PD-1)/programmed death ligand 1 (PD-L1)-based treatments have become the first-line standard of care. Despite shortcomings, PD-L1 expression level seems currently to be a relatively reliable predictor of the clinical efficacy of treatment with anti-PD-1/PD-L1 antibodies. However, additional biomarkers are required to better personalize treatment options for these patients. This review aimed to increase awareness of lung cancer and immunotherapy treatment options, depending on patient and disease stage characteristics.
{"title":"Immunotherapy for Lung Cancer","authors":"N. Karadurmuş, N. Akyürek, A. Aydıner, R. Savaş, Özlem Sönmez, M. Şendur, B. Oyan, D. Yalman, Mehmet Ufuk Yilmaz, Ülkü Yılmaz, P. Yumuk, E. Göker","doi":"10.37047/jos.2022-92712","DOIUrl":"https://doi.org/10.37047/jos.2022-92712","url":null,"abstract":"ABS TRACT Lung cancer is one of the leading causes of cancer-related deaths in men and women. Similar to the approach with other cancer types, lung cancer staging is crucial in planning an effective treatment plan and predicting patient prognosis. Effective immunotherapies for patients with non-small cell lung cancer and non-genomic driver mutations are rapidly evolving. Moreover, anti-programmed death receptor-1 (PD-1)/programmed death ligand 1 (PD-L1)-based treatments have become the first-line standard of care. Despite shortcomings, PD-L1 expression level seems currently to be a relatively reliable predictor of the clinical efficacy of treatment with anti-PD-1/PD-L1 antibodies. However, additional biomarkers are required to better personalize treatment options for these patients. This review aimed to increase awareness of lung cancer and immunotherapy treatment options, depending on patient and disease stage characteristics.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69824031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mehmet KAPAN, Erdoğan ÖZGÜR, Melek ÜNÇEL, Sait KİTAPLI, Özgür TANRIVERDI, Ali ALKAN
ABS TRACT Approximately 4% of the patients present with distant metastasis in breast cancer at the time of presentation, with many more developing the distant disease subsequently. A rare site for metastases is the head and neck. Herein, we present a case of nasal septum metastasis from breast cancer. A female patient presented with a mass in the right breast with the diagnosis of breast cancer. She presented with bi-lateral pulmonary and bony lesions, after 2 years of follow-up. Vinorelbine therapy was continued, and the patient presented with refractory epistaxis. On physical examination, a reddish and fragile mass in the left nasal cavity was detected. Bleeding was controlled using compressive measures. The excisional biopsy revealed invasive ductal carcinoma metastasis. Breast cancer metastasis to the nasal cavity is extremely rare. Clinicians should consider metastasis in cases of treatment-resistant epistaxis, nasal obstruction, and visual impairment.
{"title":"Breast Cancer Metastasis to Nasal Septum","authors":"Mehmet KAPAN, Erdoğan ÖZGÜR, Melek ÜNÇEL, Sait KİTAPLI, Özgür TANRIVERDI, Ali ALKAN","doi":"10.37047/jos.2022-94489","DOIUrl":"https://doi.org/10.37047/jos.2022-94489","url":null,"abstract":"ABS TRACT Approximately 4% of the patients present with distant metastasis in breast cancer at the time of presentation, with many more developing the distant disease subsequently. A rare site for metastases is the head and neck. Herein, we present a case of nasal septum metastasis from breast cancer. A female patient presented with a mass in the right breast with the diagnosis of breast cancer. She presented with bi-lateral pulmonary and bony lesions, after 2 years of follow-up. Vinorelbine therapy was continued, and the patient presented with refractory epistaxis. On physical examination, a reddish and fragile mass in the left nasal cavity was detected. Bleeding was controlled using compressive measures. The excisional biopsy revealed invasive ductal carcinoma metastasis. Breast cancer metastasis to the nasal cavity is extremely rare. Clinicians should consider metastasis in cases of treatment-resistant epistaxis, nasal obstruction, and visual impairment.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"83 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134888001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effects of Healthy Nutrition Barriers on the Quality of Life, Body Composition, and Depression Status of Breast Cancer Patients","authors":"Dilşat BAŞ, Nihan ÇAKIR BİÇER","doi":"10.37047/jos.2023-97828","DOIUrl":"https://doi.org/10.37047/jos.2023-97828","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134889792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Kus, Nuriye YILDIRIM ÖZDEMİR, G. Aktas, O. Sütçüoğlu, Ü. Yalcintas Arslan, M. Dirikoç, F. Köse, G. Akkus, H. Yeşil Çınkır, A. Özet
ABS TRACT Objective: In advanced gastric cancer (AGC), peritoneal metastasis (PM) is associated with poor prognosis and worse perfor- mance status (PS), which makes chemotherapy administration difficult. However, PM can present with many different clinical pictures. The aim of this study was to investigate the benefits and toxicity of taxane addition to platinum-fluoropyrimidine combination in clinically poor (CPPG) and good prognostic groups (CGPG) of AGC patients with PM. Material and Methods: A total of 172 AGC patients with PM who were treated with taxane plus platinum plus fluoropyrimidine (TPF) or platinum plus fluoropyrimidine (PF) were included in the study. The patients with massive ascites or PS 2-3 or inadequate oral intake were included in the CPPG group, while those with an absence of these clinical factors were included in the CGPG group. The efficacy and toxicity of dose intensity on survival were evaluated separately for each group using the Kaplan-Meier method. Results: At the baseline, 16.9% of all patients had massive ascites, 30.2% had PS of ≥ 2, and 33.7% had inadequate oral intake. Accordingly, 50.6% of the patients were in CPPG. The overall survival times were found to be similar in patients treated with TPF as well as those treated with PF. Moreover, the addition of taxane treatment did not have any effect on either the poor prognostic group or the good prognostic group. However, as the dose intensity was increased, the grade 3/4 toxicity, dose delay, and reduction rates also increased. Conclusion: Addition of taxane to PF did not contribute to survival in AGC patients with peritoneal metastasis, independent of the clinical prognostic group.
{"title":"Benefits and Toxicity of Taxane Addition to Platinum- Fluoropyrimidine Combination in Gastric Cancer Patients with Peritoneal Metastasis","authors":"T. Kus, Nuriye YILDIRIM ÖZDEMİR, G. Aktas, O. Sütçüoğlu, Ü. Yalcintas Arslan, M. Dirikoç, F. Köse, G. Akkus, H. Yeşil Çınkır, A. Özet","doi":"10.37047/jos.2022-90537","DOIUrl":"https://doi.org/10.37047/jos.2022-90537","url":null,"abstract":"ABS TRACT Objective: In advanced gastric cancer (AGC), peritoneal metastasis (PM) is associated with poor prognosis and worse perfor- mance status (PS), which makes chemotherapy administration difficult. However, PM can present with many different clinical pictures. The aim of this study was to investigate the benefits and toxicity of taxane addition to platinum-fluoropyrimidine combination in clinically poor (CPPG) and good prognostic groups (CGPG) of AGC patients with PM. Material and Methods: A total of 172 AGC patients with PM who were treated with taxane plus platinum plus fluoropyrimidine (TPF) or platinum plus fluoropyrimidine (PF) were included in the study. The patients with massive ascites or PS 2-3 or inadequate oral intake were included in the CPPG group, while those with an absence of these clinical factors were included in the CGPG group. The efficacy and toxicity of dose intensity on survival were evaluated separately for each group using the Kaplan-Meier method. Results: At the baseline, 16.9% of all patients had massive ascites, 30.2% had PS of ≥ 2, and 33.7% had inadequate oral intake. Accordingly, 50.6% of the patients were in CPPG. The overall survival times were found to be similar in patients treated with TPF as well as those treated with PF. Moreover, the addition of taxane treatment did not have any effect on either the poor prognostic group or the good prognostic group. However, as the dose intensity was increased, the grade 3/4 toxicity, dose delay, and reduction rates also increased. Conclusion: Addition of taxane to PF did not contribute to survival in AGC patients with peritoneal metastasis, independent of the clinical prognostic group.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69822889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Yıldırım, D. Güven, E. Chalabiyev, H. Taban, F. Yilmaz, S. Yasar, F. Kuş, A. Akyildiz, Süleyman Çağın Gürbüz, Hüseyin Sayin, G. Kavgaci, Ş. Yalçın, Ö. Dizdar
ABS TRACT Objective: Surgery followed by chemotherapy with or without radiotherapy and perioperative chemotherapy represents the standard treatment modality in locally advanced gastric cancer patients. Adjuvant radiotherapy has been shown to have no benefits in these patients, especially those undergoing D2 dissection without neoadjuvant treatment. The goal of our study was to identify the prognostic fac- tors associated with adjuvant treatments, particularly radiotherapy. Material and Methods: We evaluated the clinical, laboratory, and histological features and survival in locally advanced gastric cancer patients who underwent upfront gastric resection without neoadjuvant therapy and were subsequently treated with adjuvant chemotherapy comprising capecitabine-oxaliplatin. Parameters with significant p-values in univariate analysis were included in multivariate Cox regression analysis. Results: A total of 56 patients were included, and the median follow- up period was 33.2 months. The mean age was 61.23±8.89 years. The median disease-free survival (DFS) was 37.80 months (95% confidence interval: 22.30-53.30). The 5-year DFS and overall survival (OS) rates were 43.4% and 60.8%, respectively. In univariate analysis, lymph node involvement, diffuse histology, presence of lymphovascular invasion, positive surgical margin, presence of perineural invasion, absence of radiotherapy, and high lactate dehydrogenase (LDH) levels were found to be associated with shorter DFS and OS. In multivariate Cox re- gression analysis, diffuse histology, absence of radiotherapy, and high LDH levels were found to be associated with shorter DFS and OS. Conclusion: The long-term survival rates in our study were encouraging. Inflammatory markers, tumor histology, and radiotherapy might have prognostic value in identifying high-risk patients who could benefit from intensive therapy.
{"title":"Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy","authors":"H. Yıldırım, D. Güven, E. Chalabiyev, H. Taban, F. Yilmaz, S. Yasar, F. Kuş, A. Akyildiz, Süleyman Çağın Gürbüz, Hüseyin Sayin, G. Kavgaci, Ş. Yalçın, Ö. Dizdar","doi":"10.37047/jos.2022-92230","DOIUrl":"https://doi.org/10.37047/jos.2022-92230","url":null,"abstract":"ABS TRACT Objective: Surgery followed by chemotherapy with or without radiotherapy and perioperative chemotherapy represents the standard treatment modality in locally advanced gastric cancer patients. Adjuvant radiotherapy has been shown to have no benefits in these patients, especially those undergoing D2 dissection without neoadjuvant treatment. The goal of our study was to identify the prognostic fac- tors associated with adjuvant treatments, particularly radiotherapy. Material and Methods: We evaluated the clinical, laboratory, and histological features and survival in locally advanced gastric cancer patients who underwent upfront gastric resection without neoadjuvant therapy and were subsequently treated with adjuvant chemotherapy comprising capecitabine-oxaliplatin. Parameters with significant p-values in univariate analysis were included in multivariate Cox regression analysis. Results: A total of 56 patients were included, and the median follow- up period was 33.2 months. The mean age was 61.23±8.89 years. The median disease-free survival (DFS) was 37.80 months (95% confidence interval: 22.30-53.30). The 5-year DFS and overall survival (OS) rates were 43.4% and 60.8%, respectively. In univariate analysis, lymph node involvement, diffuse histology, presence of lymphovascular invasion, positive surgical margin, presence of perineural invasion, absence of radiotherapy, and high lactate dehydrogenase (LDH) levels were found to be associated with shorter DFS and OS. In multivariate Cox re- gression analysis, diffuse histology, absence of radiotherapy, and high LDH levels were found to be associated with shorter DFS and OS. Conclusion: The long-term survival rates in our study were encouraging. Inflammatory markers, tumor histology, and radiotherapy might have prognostic value in identifying high-risk patients who could benefit from intensive therapy.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69824024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ö. Sever, A. Bahceci, H. Yeşil Çınkır, Mustafa Yıldırım
ABS TRACT Objective: In recent years, agents targeting the androgen signaling pathway, such as abiraterone and enzalutamide, have be- come increasingly crucial in the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study aimed to compare the effectiveness of both agents retrospectively. Material and Methods: Patients with the diagnosis of mCRPC who received abiraterone (ABI group) or enzalutamide (ENZA group) and who were followed up and treated in our clinics were analyzed retrospectively. Results: A total of 59 patients, 23 receiving abiraterone and 36 enzalutamide, were included in the study. Moreover, the prostate-specific antigen (PSA) level reduced by more than 50% in 33 (14 in the ABI group and 19 in the ENZA group) patients. The median progression-free survival (PFS) and overall survival-2 (OS-2) were 7.46±2.08 months and 13.60±6.19 months in the ABI group and 8.80±4.21 months and 21.03±3.84 months in the ENZA group (p=0.448; p=0.571), respectively. When the Cox regression analysis was performed, PSA reduction of more than 50% was statistically significant for OS-2 but not for PFS (p=0.023). Conclusion: Both abiraterone and enzalutamide are effective treatment agents for mCRPC. The decrease in the PSA value is a crucial predictive marker in evaluating the effectiveness of the treatment.
{"title":"Our Experience with Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer: Retrospective Real-Life Data","authors":"Ö. Sever, A. Bahceci, H. Yeşil Çınkır, Mustafa Yıldırım","doi":"10.37047/jos.2021-85879","DOIUrl":"https://doi.org/10.37047/jos.2021-85879","url":null,"abstract":"ABS TRACT Objective: In recent years, agents targeting the androgen signaling pathway, such as abiraterone and enzalutamide, have be- come increasingly crucial in the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study aimed to compare the effectiveness of both agents retrospectively. Material and Methods: Patients with the diagnosis of mCRPC who received abiraterone (ABI group) or enzalutamide (ENZA group) and who were followed up and treated in our clinics were analyzed retrospectively. Results: A total of 59 patients, 23 receiving abiraterone and 36 enzalutamide, were included in the study. Moreover, the prostate-specific antigen (PSA) level reduced by more than 50% in 33 (14 in the ABI group and 19 in the ENZA group) patients. The median progression-free survival (PFS) and overall survival-2 (OS-2) were 7.46±2.08 months and 13.60±6.19 months in the ABI group and 8.80±4.21 months and 21.03±3.84 months in the ENZA group (p=0.448; p=0.571), respectively. When the Cox regression analysis was performed, PSA reduction of more than 50% was statistically significant for OS-2 but not for PFS (p=0.023). Conclusion: Both abiraterone and enzalutamide are effective treatment agents for mCRPC. The decrease in the PSA value is a crucial predictive marker in evaluating the effectiveness of the treatment.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69821490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：